Pfizer Inc. (NYSE:PFE) Shares Sold by Bank of New Hampshire

Bank of New Hampshire trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 8.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,421 shares of the biopharmaceutical company’s stock after selling 556 shares during the quarter. Bank of New Hampshire’s holdings in Pfizer were worth $178,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. GoalVest Advisory LLC increased its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter valued at $32,000. VisionPoint Advisory Group LLC grew its position in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners purchased a new position in Pfizer in the 4th quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in Pfizer in the 4th quarter valued at $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.0 %

NYSE PFE opened at $27.75 on Friday. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $38.99. The company has a 50-day moving average of $27.67 and a 200-day moving average of $27.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The company has a market cap of $157.22 billion, a P/E ratio of -462.34, a P/E/G ratio of 1.09 and a beta of 0.70.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the company posted $1.23 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.06%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, June 17th. BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Finally, Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.